We understand the biomarker-driven oncology drug development paradigm. Anatomic Pathology is a vital part of the study and treatment of disease, and is used for the diagnosis and prognosis of cancer to guide treatment decision-making in oncology. We provide you with value our access to commercial and clinical laboratories and a full in-house global Anatomic Pathology (AP) service with a foot print in the Americas, Europe, Asia-Pac and China, including more than 20 expert pathologists, and a lab operations team who are adept at assay transfer and validation. We use this expertise to create tailored solutions that support your oncology research from discovery to post-market.
At Q2 Solutions we offer end-to-end-precision medicine services, biomarker identification, validation, patient profiling, and companion diagnostics (CDx) to help you identify the right pathways, biomarkers and patient populations that will enable you to better predict the long-term safety and efficacy of your oncology products. Q2 Solutions can provide customized,
global laboratory solutions specifically suited for the unique combinations of therapeutic indication and targeted
mechanism-of-action driving oncology drug development.
“Our first year would not have been possible without the support of our incredible customers, employees, and parent organizations. We are proud to celebrate 1 year of a shared commitment to quality, customer service and – above all – helping bring new treatments to patients ”